Genertec Universal Medical Group Company Limited

DB:5UM Stock Report

Market Cap: €1.1b

Genertec Universal Medical Group Valuation

Is 5UM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 5UM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 5UM (€0.57) is trading below our estimate of fair value (€1.36)

Significantly Below Fair Value: 5UM is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 5UM?

Key metric: As 5UM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 5UM. This is calculated by dividing 5UM's market cap by their current earnings.
What is 5UM's PE Ratio?
PE Ratio4.2x
EarningsCN¥2.06b
Market CapCN¥8.62b

Price to Earnings Ratio vs Peers

How does 5UM's PE Ratio compare to its peers?

The above table shows the PE ratio for 5UM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average44.4x
GLJ Grenke
9.1x25.2%€678.6m
ALG ALBIS Leasing
12.6x9.9%€56.0m
HYQ Hypoport
38x28.9%€1.2b
EBEN aifinyo
118xn/a€13.3m
5UM Genertec Universal Medical Group
4.2x6.8%€9.2b

Price-To-Earnings vs Peers: 5UM is good value based on its Price-To-Earnings Ratio (4.2x) compared to the peer average (44.4x).

Price to Earnings Ratio vs Industry

How does 5UM's PE Ratio compare vs other companies in the European Diversified Financial Industry?

7 CompaniesPrice / EarningsEstimated GrowthMarket Cap
5UM 4.2xIndustry Avg. 11.2xNo. of Companies13PE01020304050+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 5UM is good value based on its Price-To-Earnings Ratio (4.2x) compared to the European Diversified Financial industry average (11.2x).

Price to Earnings Ratio vs Fair Ratio

What is 5UM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

5UM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio4.2x
Fair PE Ratio13.9x

Price-To-Earnings vs Fair Ratio: 5UM is good value based on its Price-To-Earnings Ratio (4.2x) compared to the estimated Fair Price-To-Earnings Ratio (13.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 5UM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.57
€0.82
+43.2%
16.1%€1.00€0.70n/a3
Dec ’25€0.55
€0.82
+48.4%
16.1%€1.00€0.70n/a3
Nov ’25€0.53
€0.82
+55.5%
16.1%€1.00€0.70n/a3
Oct ’25€0.53
€0.82
+55.5%
16.1%€1.00€0.70n/a3
Sep ’25€0.46
€0.83
+80.8%
14.8%€0.99€0.69n/a3
Aug ’25€0.46
€0.82
+80.6%
18.8%€1.02€0.64n/a3
Jul ’25€0.48
€0.83
+72.0%
18.7%€1.02€0.64n/a3
Jun ’25€0.51
€0.83
+64.1%
18.7%€1.02€0.64n/a3
May ’25€0.51
€0.73
+43.9%
13.3%€0.83€0.64n/a2
Apr ’25€0.47
€0.73
+53.6%
15.2%€0.84€0.61n/a2
Mar ’25€0.47
€0.73
+54.3%
15.2%€0.84€0.61n/a2
Feb ’25€0.46
€0.83
+80.6%
20.3%€1.03€0.62n/a3
Jan ’25€0.50
€0.78
+55.6%
19.7%€1.02€0.61n/a5
Dec ’24€0.49
€0.78
+60.1%
19.7%€1.02€0.61€0.555
Nov ’24€0.46
€0.83
+81.1%
17.6%€1.03€0.62€0.534
Oct ’24€0.45
€0.84
+84.1%
16.2%€1.01€0.61€0.535
Sep ’24€0.46
€0.84
+81.0%
16.2%€1.01€0.61€0.465
Aug ’24€0.47
€0.84
+77.1%
15.9%€1.00€0.61€0.465
Jul ’24€0.49
€0.84
+72.7%
15.9%€1.00€0.61€0.485
Jun ’24€0.53
€0.91
+72.5%
9.7%€1.04€0.81€0.514
May ’24€0.58
€0.90
+54.6%
21.3%€1.20€0.62€0.515
Apr ’24€0.54
€0.90
+67.3%
21.2%€1.21€0.62€0.475
Mar ’24€0.54
€0.90
+67.4%
23.4%€1.22€0.63€0.474
Feb ’24€0.55
€0.90
+63.7%
23.2%€1.21€0.63€0.464
Jan ’24€0.55
€0.92
+67.5%
26.3%€1.30€0.63€0.504
Dec ’23€0.49
€0.94
+91.8%
27.1%€1.34€0.65€0.494

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 00:23
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genertec Universal Medical Group Company Limited is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBOCOM International Securities Limited
Yolanda YinCGS International
Yolanda YinChina Galaxy International Securities (Hong Kong)